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Abstract
Background: Xenoantigens are a major source of concern with regard to the success of interspecific xenografts.
GGTA1 encodes α1,3-galactosyltransferase, which is essential for the biosynthesis of galactosyl-alpha 1,3-galactose,
the major xenoantigen causing hyperacute rejection. GGTA1-modified pigs, therefore, are promising donors for pig-
to-human xenotransplantation. In this study, we developed a method for the introduction of the CRISPR/Cas9
system into in vitro-fertilized porcine zygotes via electroporation to generate GGTA1-modified pigs.
Results: We designed five guide RNAs (gRNAs) targeting distinct sites in GGTA1. After the introduction of the Cas9
protein with each gRNA via electroporation, the gene editing efficiency in blastocysts developed from zygotes was
evaluated. The gRNA with the highest gene editing efficiency was used to generate GGTA1-edited pigs. Six piglets
were delivered from two recipient gilts after the transfer of electroporated zygotes with the Cas9/gRNA complex.
Deep sequencing analysis revealed that five out of six piglets carried a biallelic mutation in the targeted region of
GGTA1, with no off-target events. Furthermore, staining with isolectin B4 confirmed deficient GGTA1 function in
GGTA1 biallelic mutant piglets.
Conclusions: We established GGTA1-modified pigs with high efficiency by introducing a CRISPR/Cas9 system into
zygotes via electroporation. Multiple gene modifications, including knock-ins of human genes, in porcine zygotes
via electroporation may further improve the application of the technique in pig-to-human xenotransplantation.
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Background
Gene-modified pigs are ideal experimental animal
models of human disease and donors for pig-to-human
xenotransplantation [1–3]. As the life expectancy of
humans increases, the incidences of chronic diseases and
end-stage organ failure as well as demand for organ
transplantation increase [2, 3]. In the context of a short-
age in human organs for transplantation, pigs have
gained importance as an alternative source. However,
xenoantigens are a major source of concern for interspe-
cific xenografts. Antibody–xenoantigen complexes lead
to complement activation and immediate hyperacute re-
jection [4]. The major xenoantigen expressed in porcine
tissues is the galactosyl-alpha 1,3-galactose (Galα(1,
3)Gal) epitope, which is expressed on the surface of por-
cine endothelial cells and causes hyperacute rejection [3,
5].
α1,3-Galactosyltransferase, encoded by the glycopro-
tein galactosyltransferase alpha 1,3 (GGTA1), is essential
for the biosynthesis of Galα(1,3)Gal [5]. The
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establishment of GGTA1-deficient pigs lacking the func-
tional Galα(1,3)Gal epitope is a key step in controlling
xenograft rejection. Since its establishment, somatic cell
nuclear transfer (SCNT) has been the primary method for
the generation of genetically modified pigs [6, 7]. Recently,
gene editors such as zinc finger nuclease [8], transcription
activator-like effector nuclease [9], and the clustered regu-
larly interspaced short palindromic repeat (CRISPR)/
CRISPR-associated (CRISPR/Cas) system [10–12], have
improved gene modification activities markedly, including
site-specific modification and gene knock-ins and knock-
outs. Gene editors have also enabled gene modification in
porcine zygotes via direct injection into the cytoplasm [7].
However, micromanipulator systems for microinjections
of gene editors or for nuclear transfer of donor cells in
SCNT require sophisticated techniques, which limits the
widespread generation of gene-modified pigs [6].
We recently developed the gene editing by electropor-
ation of Cas9 protein (GEEP) method [13] in which the
CRISPR/Cas9 system (Cas9 protein and guide RNA
(gRNA)) is introduced into porcine zygotes by electro-
poration to disrupt a target gene. We also demonstrated
that Cas9 mRNA electroporation into porcine zygotes
resulted in a low gene-editing efficiency compared with
Cas9 protein electroporation [13]. The electroporation
procedure does not require sophisticated micromanipu-
lation techniques. However, the efficiency of gene edit-
ing by GEEP and characteristics of piglets derived from
electroporated zygotes have not been evaluated well, un-
like in SCNT, in which the generation of genetically
engineered pigs has been evaluated comprehensively
[14]. To confirm the validity and efficacy of the ap-
proach, studies on the generation of genetically modified
pigs from electroporated zygotes targeting various genes
are required. GGTA1 knockout pigs have been generated
by SCNT [15–18], handmade cloning [19], and CRISPR/
Cas9 microinjection into zygotes [20]; however, GGTA1-
modified pigs have not been established by the electro-
poration of the CRISPR/Cas9 system into zygotes.
In this study, we generated GGTA1-edited pigs using
the GEEP method to establish a resource to facilitate
pig-to-human xenotransplantation studies and to con-
firm the efficiency of the method in the establishment of
lines of genetically modified pigs.
Results
Experiment 1: comparison of the gene editing efficiency
using different gRNAs
Five types of gRNA were designed (gRNA1–5) to target
GGTA1 (Fig. 1a). Each gRNA with the Cas9 protein was
Fig. 1 Confirmation of the gRNA gene-targeting efficiency. a: gRNA sequences targeting the GGTA1 gene and genomic structure of the GGTA1
locus. b: Blastocyst formation rates of the electroporated zygotes. For each treatment group, four replicates with 199–243 oocytes per treatment
were analyzed. Values of means ± SEM are shown. c: Percentage of blastocysts carrying mutations in the GGTA1 target region after zygote
electroporation with the Cas9 protein and each gRNA targeting GGTA1. The percentage of mutant blastocysts was defined as the ratio of mutant
blastocysts to the total blastocysts. Percentages of mutant blastocysts was analyzed by chi-squared tests. a–dValues with different superscripts
differ significantly (p < 0.05) and labels containing the same letter mean no significant difference. d: Genotypes of blastocysts determined by TIDE.
WT, wild-type; Biallelic, biallelic mutant; Mosaic, mosaic mutant. Numbers above the bars indicate the total number of blastocysts examined
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introduced into in vitro-fertilized zygotes by electropor-
ation (five 1-ms square pulses at 25 V) of 100 ng/μl gRNA
and 100 ng/μl Cas9 protein. The electroporation condi-
tions have been evaluated in our previous study [21].
Thereafter, the blastocyst formation rate from electropo-
rated embryos with introduced gRNA and the genotypes
of obtained blastocysts were analyzed to evaluate their
ability to develop to the blastocyst stage and the genome
editing efficiency of each gRNA. No significant differences
in blastocyst formation rates were observed among the ex-
perimental groups (Fig. 1b). The genotypes of blastocysts
were determined by sanger sequencing and subsequent
analysis using the TIDE (tracking of indels by decompos-
ition) bioinformatics package [22]. In the present study,
blastocysts carrying more than one type of mutation and
the wild-type (WT) sequence were defined as mosaics.
The proportion of mutant blastocysts harboring mosaic
and biallelic mutants after the introduction of gRNA5 was
significantly higher than the proportions after the intro-
duction of other gRNAs (p < 0.05) (Fig. 1c). Using the
Cas9/gRNA5 complex, 37.5% of blastocysts carried bialle-
lic mutations (Fig. 1d). Although mosaicism complicates
phenotypic analysis, non-mosaic GGTA1-deficient pigs
can be generated by the subsequent breeding of F0 pigs
carrying mosaic mutations. Therefore, we selected gRNA5
for use in the generation of GGTA1-edited pigs.
Experiment 2: generation and analysis of GGTA1-edited
piglets
Cas9 protein and gRNA5 were introduced into approxi-
mately 400 zygotes by electroporation. Then, these zy-
gotes were transferred into the oviducts of two recipient
gilts (approximately 200 zygotes/gilts). Both recipient
gilts became pregnant and gave birth to a total of six
piglets. A deep sequencing analysis of DNA samples de-
rived from ear biopsy samples of the delivered piglets
was performed to evaluate gene editing in the target
gene and off-target events. Deep sequencing of the
GGTA1 genomic regions flanking the target sites
revealed that five out of the six piglets carried mutations
in GGTA1 (Fig. 2). None of the five piglets (#1, #2, #3,
#4, and #5) had WT sequences; therefore, they were
considered biallelic mutants. For an off-target analysis,
we searched the whole genome sequence of the pig
[UCSC (University of California, Santa Cruz) Genome
Browser SGSC Sscrofa10.2/susScr3 assembly] for poten-
tial off-target sites and found six sites for gRNA5 with
less than four mismatches/gaps (Fig. 3a). In a deep-
sequencing analysis, we did not detect mutations at off-
target sites in more than 99% of the amplicons (Fig. 3b).
The remaining 1% was composed of a small number of
amplicons (< 0.1%) carrying different sequences.
The expression levels of the Galα(1,3)Gal epitope in
heart, lung, liver, pancreas, and kidney tissues were
assessed by staining using isolectin B4. The tissues de-
rived from a GGTA1 biallelic mutant piglet (#1) and its
WT littermate (#6) were stained with Alexa 488-labeled
isolectin B4 to analyze Galα(1,3)Gal epitope expression.
A histological analysis indicated a deficiency in GGTA1
in the GGTA1 biallelic mutant piglet (Fig. 4). The deep
sequencing analysis of the genomic DNA derived from
the heart, lung, liver, pancreas, and kidney of piglet #1
confirmed that these organs harbored the same type of
mutations observed in the ear biopsy analyses; however,
the frequency of these mutations varied with the organs
(Fig. 5). Galα(1,3)Gal epitope expression was also
assessed in ear biopsy samples from the other piglets
(#2, #3, #4 and #5) and compared with that from a WT
littermate (#6) (Fig. 6). Downregulation of Galα(1,3)Gal
expression was observed in piglets #2, #3, and #4. The
expression of Galα(1,3)Gal in Piglet #5 carrying in-frame
mutation was similar to that in the WT.
Finally, we investigated whether the mutation detected
in the F0 pig was inherited by the subsequent gener-
ation. We generated the F1 generation offspring by mat-
ing pig #2 (male) with #5 (female). Eight F1 piglets were
delivered, and the piglets harbored mutations detected
in the ear biopsy samples from pigs #2 and #5 (Fig. 7).
Fig. 2 Deep sequence analysis of the GGTA1 target region in delivered piglets. *Nucleotides in blue and red represent the target sequences and
PAM sequences of each gRNA, respectively. Nucleotides in green and yellow represent inserted and modified sequences, respectively. **The
frequency was defined as the ratio of the number of amplicons to the total read number. ***The mutation rate was defined as the ratio of the
total number of mutant amplicons to the total read number. WT, wild-type; ♂, male; ♀, female
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Discussion
In the present study, we successfully generated GGTA1
biallelic mutant pigs using the GEEP method based on
the CRISPR/Cas9 system with high efficiency and no
off-target events. The assessment of Galα(1,3)Gal epi-
tope expression in ear biopsy samples and organ samples
indicated that GGTA1 biallelic mutant pigs without in-
frame mutations exhibit the successful downregulation
of the Galα(1,3)Gal epitope. Conversely, high frequency
in-frame mutation (45.9%) seemed to result in the
expression of Galα(1,3)Gal in one biallelic mutant piglet
(#5).
Non-specific cleavage of off-target sequences are a
major concern with respect to the practical implementa-
tion of the CRISPR/Cas9 system [23, 24]. In a deep se-
quencing analysis, more than 99% of the amplicons of
potential off-target sites were made up of the WT se-
quence. The remaining 1% was composed of a small
number of amplicons (< 0.1%) carrying different se-
quences. These were also detected when we analyzed a
Fig. 3 Off-target analysis of the delivered piglets via deep sequencing. a: Genome sequences and positions of possible off-target sites.
Nucleotides in blue and red represent the target sequences and the PAM sequences of gRNA5, respectively. Nucleotides in green represent
mismatches with the gRNA5 sequence. b: Frequency of the WT sequence at possible off-target sites
Fig. 4 Immunohistochemical assessment of wild-type and GGTA1 biallelic mutant piglets. The heart, lung, liver, pancreas, and kidney tissues
derived from wild-type (WT) and GGTA1 biallelic mutant piglets (#1) were immunohistochemically stained for αGal (green) and counterstained
with DAPI (blue). The scale bar in each panel represents 50 μm
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WT piglet by deep sequencing [13, 25], indicating that
they may have been introduced by polymerase chain re-
action (PCR) errors or sequencing errors. In addition,
we introduced the CRISPR/Cas9 system into 1-cell-stage
zygotes, indicating that off-target mutation carrying less
than 0.1% of the sequences in individual offspring is dif-
ficult to achieve. Therefore, we concluded that no off-
target events were detected in GGTA1 mutant pigs gen-
erated in the present study. Varying degrees of off-target
effects by CRISPR/Cas9 have been observed in cells [26,
27], and whole-genome sequencing analyses have
identified off-target events in founder gene-modified
mice generated using the CRISPR/Cas9 system [28]. An-
other study reported that off-target events are rare in
gene-modified nonhuman primates generated using the
CRISPR/Cas9 system [29]. In our previous study of the
generation of Myostatin mutant pigs, no off-target
events were observed [13]. Recently, mutant Cas9 nucle-
ases with high specificity have been designed [30–32].
Such improvements could reduce off-target events,
which should be carefully evaluated in gene-modified
pigs supplied as founders.
In the present study, we achieved the efficient gener-
ation of GGTA1 biallelic-mutant pigs using the GEEP
method, in which the CRISPR/Cas9 system is introduced
into zygotes by electroporation. The electroporation pro-
cedure does not require any sophisticated micromanipu-
lation techniques, when compared with microinjection
and SCNT medicated procedures, and the results of the
present study demonstrated that the GEEP method is a
promising approach for the generation of biallelic mu-
tants with high efficiency. However, we have previously
observed that the introduction of CRISPR/Cas9 into zy-
gotes results in a high frequency of mosaicism in blasto-
cysts and obtained piglets [13, 33, 34]. Based on an
analysis of DNA derived from ear biopsy samples, piglet
#1 showed three types of mutation; however, there could
be differences in editing variants among the different or-
gans. We performed a deep-sequencing analysis of the
selected organs from piglet #1 for genotype
Fig. 5 Genotype of major organs derived from piglets #1 analyzed
by deep sequencing. Frequency of introduced mutations in
selected organs
Fig. 6 Comparison of the expression of αGal epitope in GGTA1 mutant piglets with various genotypes by immunohistochemical assessment. The
ear biopsy derived from wild-type (WT) and GGTA1 biallelic mutant piglets (#2, #3, #4, and #5) were immunohistochemically stained for αGal
(green) and counterstained with DAPI (blue). The scale bar in each panel represents 50 μm
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confirmation. We observed that the piglet harbored mu-
tations, as observed in the ear biopsy analysis, in its
major organs at various frequencies. Our previous study
demonstrated mosaicism of major organs with frequen-
cies similar to those observed in the results of the ear bi-
opsy analysis [35]. The frequency of genotype varies
with organ in genetically modified F0 pigs, indicating
that a careful observation of WT sequence/in-frame mu-
tation in the genomic DNA is an essential step to apply
these organs for transplantation.
The assessment of Galα(1,3)Gal expression in the
major organs of piglet #1 demonstrated downregulation
of Galα(1,3)Gal expression; however, the heart and liver
tissues contained a Galα(1,3)Gal-positive region. Such
residual amounts of Galα(1,3)Gal epitope reactivity,
which may not be tissue specific, have also been ob-
served in GGTA1 knockout pigs [36] and cells [37]. Pre-
vious studies on GGTA1 deficient pigs could not detect
Galα(1,3)Gal expression on the vascular endothelium
using the IB4 [16, 38]; therefore the α1,3-Galactosyl-
transferase has been believed to be the only enzyme that
synthesizes Gal(1,3)Gal [39]. Milland et al. suggested
that isoglobotrihexosylceramide 3 synthase (iGb3S)
could also be responsible for Galα(1,3)Gal expression in
GGTA1 deficient mice and pigs as an alternative path-
way [40]. However, Galα(1,3)Gal expression was ob-
served in GGTA1 and iGb3s double-knockout pigs [41].
Although Galα(1,3)Gal expression was successfully
downregulated by GGTA1 modification, another path-
way could have facilitated the expression of Galα(1,3)Gal
epitope in GGTA1-deficient pigs.
The direct introduction of the CRISPR/Cas9 system by
zygote microinjection also suffers a risk of mosaicism
[20, 42]. Mosaicism in the founder generation requires
subsequent breeding for phenotypic analyses. In this
study, inheritance analysis of GGTA1-modified F0 pigs
demonstrated that the spectra of alleles present in the
gametes was similar as the alleles observed in the ear bi-
opsy; therefore, we will generate nonmosaic GGTA1 de-
ficient pigs by mating using F0 pigs harboring the
desired genotypes. However, subsequent breeding of F0
lines is cost- and time-intensive. Gene modifications by
Cas9 protein/gRNA complexes remaining active during
later developmental stages, following cleavage, can lead
to mosaicism [43], which is presumed to be the reason
for the more than two different genotypes in piglet #1
and #4 in the present study. This is expected to be re-
duced by the early delivery of the CRISPR/Cas9 system
into zygotes. We previously evaluated the gene editing
efficiency of the CRISPR/Cas9 system introduced before
in vitro fertilization for the production of non-mosaic
mutants [44]. Other studies have demonstrated that the
microinjection of the CRISPR/Cas9 system into imma-
ture oocytes successfully reduces mosaicism [45, 46]. A
combination of these strategies will reduce mosaicism by
the one-step generation of gene-knockout founder pigs
via microinjection and electroporation techniques.
GGTA1 inactivation is an essential first step for con-
trolling hyperacute rejection in pig-human xenotrans-
plantation. However, other xenogeneic antigens,
including beta-1,4-N-acetyl-galactosaminyltransferase 1
(B4GALNT) [47] and N-glycolylneuraminic acid synthe-
sized by cytidine monophospho-N-acetylneuraminic acid
hydroxylase (CMAH) [48, 49], also need to be eliminated
to prolong organ survival. The triple knockout of por-
cine GGTA1, CMAH, and B4GALNT2 has been achieved
by SCNT and significantly reduces human IgG and IgM
antibody binding to porcine peripheral blood monocytes,
red blood cells [50–52], and the pericardium [53]. In
addition, to prevent hyperacute rejection by controlling
Fig. 7 Analysis of the genome sequences of F1 piglets. The alignment of sequences from F1 piglets is shown. The nucleotides in blue and red
represent the target sequences and the PAM sequences of gRNA5, respectively. The nucleotides in green represent the inserted sequences and
those in yellow represent the modified sequences
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complement activation, the expression of human com-
plement regulators in pigs has been studied [3, 54].
Other anti-inflammatory and anti-apoptosis-related
genes in humans have also been expressed in pigs [55–
57]. Xenograft rejection of these organs from genetically
modified pigs to monkey and baboon models has been
successfully delayed [58–60]. Multiple gene modifica-
tions, including knock-ins of human genes, will be es-
sential for the maintenance of the function of
xenotransplanted organs.
Conclusion
Our method to establish GGTA1-modified pigs harbor-
ing mutations in their germ lines and without antigen-
related hyperacute rejection is an efficient alternative to
SCNT. The GEEP method does not require complex
procedures. However, multiple gene-modified pigs gen-
erated using this method have not been established. To
generate gene-modified pigs for pig-to-human xeno-
transplantation, further improvements aimed at the gen-
eration of multiple gene modifications, including knock-
ins of human genes, in porcine zygotes, are required.
Methods
Animals
All animal care and experimental procedures, including
the determination of experimental endpoints, were per-
formed in accordance with the Guidelines for Animal
Experiments of Tokushima University. All animals were
housed and maintained in accordance with Institutional
Animal Care and Use Committee guidelines. Two sexu-
ally mature Landrace gilts were obtained from the
Tokushima Prefectural Livestock Research Institute
(Tokushima, Japan) as recipients. Pigs were housed in a
temperature-controlled room (25 ± 3 °C) under a 12-h
light/12-h dark cycle with free access to water and were
provided with commercial feed (JA Nishinihon Kumiai
Shiryou, Hyogo, Japan). The health condition of all pigs
was observed daily at feeding by the animal husbandry
staff under the supervision of an attending veterinarian.
To minimize animal suffering, all surgical procedures
were performed under anesthesia by the intramuscular
injection of 10 mg/kg ketamine (Ketalar, ketamine
hydrochloride, Daiichi Sankyo Pharmaceutical, Tokyo,
Japan) and continuous inhalation of 2 to 3% isoflurane
(Mylan, Osaka, Japan) in the operation room. Euthanasia
was performed by the intravenous injection of a potas-
sium chloride solution (3 mmol/kg) under deep
anesthesia by isoflurane according to the American Vet-
erinary Medical Association Guidelines for the Euthan-
asia of Animals.
In this study, we obtained a total of six piglets. Five
piglets (#1, #2, #3, #4, and #5) carried mutations in
GGTA1 gene, and one piglet was WT. For collecting
tissue samples, piglets #1 and #6 were euthanized by the
intravenous injection of a potassium chloride solution
(3 mmol/kg) under deep anesthesia by isoflurane. Piglets
#2, #3, #4, and #5 were maintained as a founder.
Oocyte collection, in vitro maturation, and fertilization
Pig ovaries were obtained from prepubertal gilts
(Landrace × Large White × Duroc breeds) at a local
slaughterhouse and were transported in physiological
saline within 1 h to the laboratory at 30 °C. Ovaries
were washed three times with prewarmed physio-
logical saline solution supplemented with 100 IU/ml
penicillin G potassium (Meiji, Tokyo, Japan) and 0.1
mg/ml streptomycin sulfate (Meiji). Follicles with di-
ameters of 3–6 mm on the ovarian surface were sliced
on a sterilized dish using a surgical blade, and
cumulus-oocyte complexes (COCs) were visualized
and collected under a stereomicroscope. Approxi-
mately 50 COCs were cultured in 500 μl of matur-
ation medium consisting of tissue culture medium
199 with Earle’s salts (TCM 199; Gibco/Invitrogen
Co., Carlsbad, CA, USA) supplemented with 10% (v/
v) porcine follicular fluid, 0.6 mM cysteine (Sigma-Al-
drich, St. Louis, MO, USA), 50 μM β-mercaptoethanol
(Wako Pure Chemical Industries Ltd., Osaka, Japan),
50 μM sodium pyruvate (Sigma-Aldrich), 2 mg/ml D-
sorbitol (Wako Pure Chemical Industries Ltd.), 10 IU/
ml equine chorionic gonadotropin (eCG; Kyoritu
Seiyaku, Tokyo, Japan), 10 IU/ml human chorionic go-
nadotropin (hCG; Kyoritu Seiyaku), and 50 μg/ml gen-
tamicin (Sigma-Aldrich), then covered with mineral
oil (Sigma-Aldrich) for 22 h in 4-well dishes (Nunc
A/S, Roskilde, Denmark). The COCs were transferred
into a maturation medium without hormones for an
additional 22 h. COCs were incubated at 39 °C in a
humidified incubator containing 5% CO2.
The matured oocytes were subjected to in vitro
fertilization as described previously [61]. Briefly, frozen-
thawed ejaculated spermatozoa were transferred into 5
ml of porcine fertilization medium (PFM; Research Insti-
tute for the Functional Peptides Co., Yamagata, Japan)
and washed by centrifugation at 500×g for 5 min. The
pelleted spermatozoa were resuspended in fertilization
medium and adjusted to 1 × 106 cells/ml. Then, approxi-
mately 50 oocytes were transferred to 500 μl of sperm-
containing fertilization medium, covered with mineral
oil in 4-well dishes, and co-incubated for 5 h at 39 °C in
a humidified incubator containing 5% CO2, 5% O2, and
90% N2. After co-incubation, the putative zygotes were
denuded from the cumulus cells and the attached
spermatozoa by mechanical pipetting, transferred to por-
cine zygote medium (PZM-5; Research Institute for the
Functional Peptides Co.), and cultured for 7 h until
electroporation.
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Electroporation
Electroporation was performed as described previously
[13]. Briefly, an electrode (LF501PT1–20; BEX, Tokyo,
Japan) was connected to a CUY21EDIT II electroporator
(BEX) and was set under a stereoscopic microscope. The
inseminated 50 zygotes were washed with Opti-MEM I
solution (Gibco/Invitrogen, Carlsbad, CA, USA) and
were placed in a line in the electrode gap in a chamber
slide filled with 10 μl of Nuclease-Free Duplex Buffer
(IDT; Integrated DNA Technologies, Coralville, IA,
USA) containing 100 ng/μl gRNA (Alt-R CRISPR
crRNAs and tracrRNA, chemically modified and length-
optimized variants of the native guide RNAs purchased
from IDT) targeting GGTA1 and 100 ng/μl Cas9 protein
(Guide-it Recombinant Cas9; Takara Bio, Shiga, Japan).
According to manufacturer’s instruction, crRNA con-
tains chemical modifications to protect it from degrad-
ation by cellular RNases, and tracrRNA contains
chemical modifications conferring high nuclease resist-
ance. gRNAs were designed using the CRISPRdirect
webtool (https://crispr.dbcls.jp/) [62]. To minimize off-
target effects, the 12 bases at the 3′ end of the designed
gRNAs had no identical sequence matches to the pig
genome other than the target region of GGTA1, as de-
termined using the COSMID webtool (https://crispr.
bme.gatech.edu/), which scores and ranks off-target can-
didate sequences based on the locations and numbers of
base mismatches, deletions, and insertions, when com-
pared to the gRNA sequence [63].
After electroporation (five 1-ms square pulses at 25 V),
the zygotes were washed with PZM-5 and were cultured
until embryo transfer (for 12 h) or for 3 days. The em-
bryos that were cultured for 3 days were subsequently
incubated in porcine blastocyst medium (PBM; Research
Institute for the Functional Peptides Co.) for 4 days to
evaluate their ability to develop to the blastocyst stage
and for blastocyst genotyping. As a control, some of the
inseminated zygotes were cultured with PZM-5 and
PBM for 7 days without electroporation. Zygotes and
embryos were incubated at 39 °C in a humidified incuba-
tor containing 5% CO2, 5% O2, and 90% N2.
Analysis of the targeted gene after electroporation
Genomic DNA was isolated from blastocysts by boil-
ing in a 50 mM NaOH solution. After neutralization,
the genomic regions flanking the gRNA target se-
quences were PCR-amplified by the following specific
primers: gRNA1 and gRNA3, 5′- AGTCAGGATG
CTTCCCCTTT − 3′ (forward) and 5′- AAGCTG
GTGACTTGGCTGAT − 3′ (reverse), gRNA2, gRNA4,
and gRNA5, 5′- AAAAGGGGAGCACTGAACCT − 3′
(forward) and 5′- ATCCGGACCCTGTTTTAAGG −
3′ (reverse). The PCR products were extracted by
agarose gel electrophoresis. The targeted genomic
regions were directly sequenced. Sanger sequencing
was performed using a BigDye Terminator Cycle Se-
quencing Kit ver. 3.1 (Thermo Fisher Scientific, Wal-
tham, MA, USA) and the ABI 3500 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). The
TIDE bioinformatics package [22] was used to deter-
mine the genotypes of blastocysts. Blastocysts were
classified as having biallelic mutations (carrying no
WT sequences), mosaics (carrying more than one
type of mutation and the WT sequence), or WT (car-
rying only the WT sequence).
Embryo transfer
Recipient gilts, the estrous cycles of which had been syn-
chronized, were prepared for embryo transfer as de-
scribed previously [64]. In brief, 0.2 mg of cloprostenol
(Planate, MSD Animal Health, Tokyo, Japan) was given
by intramuscular (i.m.) injection to pregnant gilts 35 to
53 days after the day of insemination. Subsequently, the
second i.m. injection of 0.2 mg of cloprostenol and i.m.
injection of 1000 IU of eCG (PMSA for Animal,
ZENOAQ, Fukushima, Japan) were given to the gilts 24
h after the first injection of cloprostenol. At 72 h after
the eCG i.m. injection, 1500 IU of hCG (Gestron 1500,
Kyoritsu Seiyaku) was administered to the gilts. Approxi-
mately 72 h after the eCG i.m. injection, one- to two-cell
stage embryos which were electroporated approximately
12 h before the embryo transfer were transferred into
the oviducts of a recipient gilt under anesthesia. The
gilts were placed in the supine position and the surgical
area was disinfected with povidone-iodine (Meiji Seika
Pharma, Tokyo, Japan). Generally, spontaneous ovula-
tion rate, which varies across breeds, ranges from 10 to
23 [65, 66]. Viability and quality of in vitro-derived em-
bryos are inferior to those of in vivo-derived embryos
[67], and blastocyst formation rate was around 20% in
the present study. Therefore, approximately 100 zygotes
were transferred to each oviduct, resulting in the transfer
of 200 zygotes (equivalent to approximately 40 blasto-
cysts) per gilt under sterile conditions.
Mutation analysis in piglets by deep sequencing
The ear biopsies were collected from piglets under
anesthesia by continuous inhalation of 2 to 3% isoflur-
ane. Genomic DNA was isolated from the ear biopsies
by boiling in a 50mM NaOH solution. After
neutralization, the genomic regions that flanked the
gRNA target sequences were amplified by two-step PCR
by specific primers (S1 Table) and the Index PCR
Primers following the manufacturer’s instructions (Illu-
mina, Hayward, CA, USA). After gel purification, the
amplicons were subjected to MiSeq sequencing using
the MiSeq Reagent Kit v. 2 (250 cycles) (Illumina, San
Diego, CA, USA). The mutation rates were defined as
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the ratio of the number of mutant amplicons to the total
read number. A small number of amplicons carrying dif-
ferent sequences, that were also detected in WT samples
were excluded as sequencing errors. Piglets that carried
no WT sequences were classified as having biallelic mu-
tations. Those carrying more than one type of mutation
and the WT sequence were classified as mosaics. Piglets
that carried only the WT sequence were classified as
WT.
For the evaluation of genotype in major organs, gen-
omic DNA isolated from the heart, lung, liver, pancreas,
and kidney were amplified by two-step PCR and sub-
jected to MiSeq sequencing as described above.
Off-target effects determined by deep-sequencing
Off-target analysis was performed as described previ-
ously [13]. The COSMID webtool was used to determine
the predicted off-target candidates. The genomic regions
flanking potential off-target sites were amplified by two-
step PCRs using specific primers (S2 Table) and the
Index PCR Primers following the manufacturer’s instruc-
tions (Illumina), and subjected to a MiSeq sequencing
analysis. Indel or substituted mutations were measured
within a 5-bp window around the predicted Cas9 cleav-
age site in each off-target sites using CRISPResso [68] to
minimize false-positive classification. A small number of
amplicons carrying different sequences that were also
detected in a WT sample were excluded as sequencing
errors.
Immunohistochemical assessment of piglets
A GGTA1 biallelic mutant piglet and its WT littermate
were euthanized by the intravenous injection of a potas-
sium chloride solution (3 mmol/kg) under the intramus-
cular injection of 10 mg/kg ketamine and subsequent
deep anesthesia by isoflurane. Tissues were dissected,
fixed in a 4% paraformaldehyde neutral-buffered solution
(Wako, Osaka, Japan), and manually embedded in paraf-
fin. The paraffin-embedded sections were deparaffinized
in xylene and rehydrated in decreasing concentrations of
ethanol. Blocking treatment was performed by incuba-
tion with 0.1% bovine serum albumin in phosphate buff-
ered saline supplemented with 1 mM CaCl2, 1 mM
MgCl2, and 1 mM MnCl2 for 30 min at 25 °C. The sec-
tions were incubated overnight with 10 μg/ml isolectin
B4-Alexa 488 (Thermo Fisher Scientific) at 4 °C and
were subsequently fixed with 10% neutral formalin. The
nuclei were counterstained with DAPI.
Statistical analyses
Percentage data for embryos that developed to the
blastocyst stage were subjected to arcsine transformation
before analysis of variance (ANOVA). The transformed
data were evaluated by ANOVA, followed by protected
Fisher’s least significant difference tests. The analysis
was performed using StatView software (Abacus Con-
cepts, Berkeley, CA, USA). The percentages of mutated
blastocysts were analyzed using chi-squared tests. Differ-
ences with a probability value (p) of 0.05 or less were
considered statistically significant.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12896-020-00638-7.
Additional file 1 S1 Table. Oligonucleotide sequences used for analysis
of the introduced mutations in piglets by deep sequencing. S2 Table.
Oligonucleotide sequences used for off-target analysis by deep-
sequencing.
Abbreviations
ANOVA: ANalysis Of VAriance; B4GALNT: Beta-1,4-N-acetyl-
GALactosaminylTransferase 1; Cas9: CRISPR-associated system 9;
CMAH: Cytidine Monophospho - N - acetylneuraminic Acid Hydroxylase;
COCs: Cumulus-Oocyte Complexes; CRISPR: Clustered Regularly Interspaced
Short Palindromic Repeat; eCG: Equine Chorionic Gonadotropin; gRNA: Guide
RNA; GEEP: Gene Editing by Electroporation of Cas9 Protein;
GGTA1: Glycoprotein Galactosyl Transferase Alpha 1,3; hCG: Human Chorionic
Gonadotropin; iGb3s: Isoglobotrihexosylceramide 3 synthase;
PAM: Protospacer Adjacent Motif; PBM: Porcine Blastocyst Medium;
PCR: Polymerase Chain Reaction; PFM: Porcine Fertilization Medium; PZM-
5: Porcine zygote medium-5; SCNT: Somatic Cell Nuclear Transfer;
TCM199: Tissue Culture Medium 199; TIDE: Tracking of Indels by
DEcomposition; WT: Wild-type
Acknowledgments
We thank the Nippon Food Packer, K. K. Shikoku (Tokushima, Japan) for
supplying the pig ovaries.
Authors’ contributions
F.T., M.H., and T.O. conceived the study and wrote the manuscript. F.T. and
M.H. performed the majority of experiments. T.O. designed the study,
coordinated all of the experiments, and reviewed the manuscript. M.H.
performed the phenotypic analysis. N.T.N. contributed to the laboratory work
and statistical analysis. O.S., T.K., and M.D. designed the study and revised the
manuscript. All of the authors read and accepted the manuscript.
Funding
This study was supported in part by the Program of Open Innovation
Platform with Enterprises, Research Institute and Academia (OPERA) grant
number JPMJOP1613 from the Japan Science and Technology Agency (JST),
and KAKENHI grant number JP17H03938, JP18K12062 and JP19K16014 from
the Japan Society for the Promotion of Science (JSPS). The funders had no
role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
The animal experiments were approved by the Institutional Animal Care and




The authors declare that they have no competing interests.
Tanihara et al. BMC Biotechnology           (2020) 20:40 Page 9 of 11
Author details
1Laboratory of Animal Reproduction, Faculty of Bioscience and Bioindustry,
Tokushima University, 2272-1 Ishii, Myozai-gun, Tokushima 779-3233, Japan.
2Research and Development Center, Otsuka Pharmaceutical Factory, Inc., 115
Muya-cho, Naruto, Tokushima 772-8601, Japan.
Received: 29 February 2020 Accepted: 10 August 2020
References
1. Niemann H, Kues WA. Application of transgenesis in livestock for agriculture
and biomedicine. Anim Reprod Sci. 2003;79:291–317.
2. Klymiuk N, Aigner B, Brem G, Wolf E. Genetic modification of pigs as organ
donors for xenotransplantation. Mol Reprod Dev. 2010;77:209–21.
3. Zeyland J, Lipinski D, Slomski R. The current state of xenotransplantation. J
Appl Genet. 2015;56:211–8.
4. Cooper DK. Xenoantigens and xenoantibodies. Xenotransplantation. 1998;5:
6–17.
5. Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes, and Old
World monkeys differ from other mammals in the expression of alpha-
galactosyl epitopes on nucleated cells. J Biol Chem. 1988;263:17755–62.
6. Fan N, Lai L. Genetically modified pig models for human diseases. J Genet
Genomics. 2013;40:67–73.
7. Tan W, Proudfoot C, Lillico SG, Whitelaw CB. Gene targeting, genome
editing: from Dolly to editors. Transgenic Res. 2016;25:273–87.
8. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger
fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A. 1996;93:1156–
60.
9. Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A,
Bogdanove AJ, Voytas DF. Targeting DNA double-strand breaks with TAL
effector nucleases. Genetics. 2010;186:757–61.
10. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W,
Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas
systems. Science. 2013;339:819–23.
11. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church
GM. RNA-guided human genome engineering via Cas9. Science. 2013;339:
823–6.
12. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome
editing in human cells. Elife. 2013;2:e00471.
13. Tanihara F, Takemoto T, Kitagawa E, Rao S, Do LT, Onishi A, Yamashita Y,
Kosugi C, Suzuki H, Sembon S, Suzuki S, Nakai M, Hashimoto M, Yasue A,
Matsuhisa M, Noji S, Fujimura T, Fuchimoto D, Otoi T. Somatic cell
reprogramming-free generation of genetically modified pigs. Sci Adv. 2016;
2:e1600803.
14. Kurome M, Geistlinger L, Kessler B, Zakhartchenko V, Klymiuk N, Wuensch A,
Richter A, Baehr A, Kraehe K, Burkhardt K, Flisikowski K, Flisikowska T, Merkl
C, Landmann M, Durkovic M, Tschukes A, Kraner S, Schindelhauer D, Petri T,
Kind A, Nagashima H, Schnieke A, Zimmer R, Wolf E. Factors influencing the
efficiency of generating genetically engineered pigs by nuclear transfer:
multi-factorial analysis of a large data set. BMC Biotechnol. 2013;13:43.
15. Cheng W, Zhao H, Yu H, Xin J, Wang J, Zeng L, Yuan Z, Qing Y, Li H, Jia B,
Yang C, Shen Y, Zhao L, Pan W, Zhao HY, Wang W, Wei HJ. Efficient
generation of GGTA1-null Diannan miniature pigs using TALENs combined
with somatic cell nuclear transfer. Reprod Biol Endocrinol. 2016;14:77.
16. Phelps CJ, Koike C, Vaught TD, Boone J, Wells KD, Chen SH, Ball S, Specht
SM, Polejaeva IA, Monahan JA, Jobst PM, Sharma SB, Lamborn AE, Garst AS,
Moore M, Demetris AJ, Rudert WA, Bottino R, Bertera S, Trucco M, Starzl TE,
Dai Y, Ayares DL. Production of alpha 1,3-galactosyltransferase-deficient
pigs. Science. 2003;299:411–4.
17. Xin J, Yang H, Fan N, Zhao B, Ouyang Z, Liu Z, Zhao Y, Li X, Song J, Yang Y,
Zou Q, Yan Q, Zeng Y, Lai L. Highly efficient generation of GGTA1 biallelic
knockout inbred mini-pigs with TALENs. PLoS One. 2013;8:e84250.
18. Hauschild J, Petersen B, Santiago Y, Queisser AL, Carnwath JW, Lucas-Hahn
A, Zhang L, Meng X, Gregory PD, Schwinzer R, Cost GJ, Niemann H. Efficient
generation of a biallelic knockout in pigs using zinc-finger nucleases. Proc
Natl Acad Sci U S A. 2011;108:12013–7.
19. Gao H, Zhao C, Xiang X, Li Y, Zhao Y, Li Z, Pan D, Dai Y, Hara H, Cooper DK,
Cai Z, Mou L. Production of alpha1,3-galactosyltransferase and cytidine
monophosphate-N-acetylneuraminic acid hydroxylase gene double-
deficient pigs by CRISPR/Cas9 and handmade cloning. J Reprod Dev. 2017;
63:17–26.
20. Petersen B, Frenzel A, Lucas-Hahn A, Herrmann D, Hassel P, Klein S, Ziegler
M, Hadeler KG, Niemann H. Efficient production of biallelic GGTA1 knockout
pigs by cytoplasmic microinjection of CRISPR/Cas9 into zygotes.
Xenotransplantation. 2016;23:338–46.
21. Nishio K, Tanihara F, Nguyen TV, Kunihara T, Nii M, Hirata M, Takemoto T,
Otoi T. Effects of voltage strength during electroporation on the
development and quality of in vitro-produced porcine embryos. Reprod
Domest Anim. 2018;53:313–8.
22. Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative
assessment of genome editing by sequence trace decomposition. Nucleic
Acids Res. 2014;42:e168.
23. Barman A, Deb B, Chakraborty S. A glance at genome editing with CRISPR-
Cas9 technology. Curr Genet. 2019.
24. Kimberland ML, Hou W, Alfonso-Pecchio A, Wilson S, Rao Y, Zhang S, Lu Q.
Strategies for controlling CRISPR/Cas9 off-target effects and biological
variations in mammalian genome editing experiments. J Biotechnol. 2018;
284:91–101.
25. Le QA, Hirata M, Nguyen NT, Takebayashi K, Wittayarat M, Sato Y, Namula Z,
Nii M, Tanihara F, Otoi T. Effects of electroporation treatment using different
concentrations of Cas9 protein with gRNA targeting Myostatin (MSTN)
genes on the development and gene editing of porcine zygotes. Anim Sci
J. 2020;91:e13386.
26. Cho SW, Kim S, Kim Y, Kweon J, Kim HS, Bae S, Kim JS. Analysis of off-target
effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases.
Genome Res. 2014;24:132–41.
27. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD. High-
frequency off-target mutagenesis induced by CRISPR-Cas nucleases in
human cells. Nat Biotechnol. 2013;31:822–6.
28. Dong Y, Li H, Zhao L, Koopman P, Zhang F, Huang JX. Genome-Wide Off-
Target Analysis in CRISPR-Cas9 Modified Mice and Their Offspring. G3
(Bethesda). 2019;9:3645–51.
29. Kang Y, Chu C, Wang F, Niu Y. CRISPR/Cas9-mediated genome editing in
nonhuman primates. Dis Model Mech. 2019;12.
30. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally
engineered Cas9 nucleases with improved specificity. Science. 2016;351:
84–8.
31. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung
JK. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide
off-target effects. Nature. 2016;529:490–5.
32. Lee JK, Jeong E, Lee J, Jung M, Shin E, Kim YH, Lee K, Jung I, Kim D, Kim S,
Kim JS. Directed evolution of CRISPR-Cas9 to increase its specificity. Nat
Commun. 2018;9:3048.
33. Tanihara F, Hirata M, Nguyen NT, Le QA, Hirano T, Takemoto T, Nakai M,
Fuchimoto DI, Otoi T. Generation of a TP53-modified porcine cancer model
by CRISPR/Cas9-mediated gene modification in porcine zygotes via
electroporation. PLoS One. 2018;13:e0206360.
34. Tanihara F, Hirata M, Nguyen NT, Le QA, Hirano T, Takemoto T, Nakai M,
Fuchimoto DI, Otoi T. Generation of PDX-1 mutant porcine blastocysts by
introducing CRISPR/Cas9-system into porcine zygotes via electroporation.
Anim Sci J. 2019;90:55–61.
35. Tanihara F, Hirata M, Thi Nguyen N, Anh Le Q, Hirano T, Otoi T. Generation
of viable PDX1 gene-edited founder pigs as providers of nonmosaics. Mol
Reprod Dev. 2020;87:471–81.
36. Wang RG, Ruan M, Zhang RJ, Chen L, Li XX, Fang B, Li C, Ren XY, Liu JY,
Xiong Q, Zhang LN, Jin Y, Li L, Li R, Wang Y, Yang HY, Dai YF. Antigenicity
of tissues and organs from GGTA1/CMAH/beta4GalNT2 triple gene
knockout pigs. J Biomed Res. 2018.
37. Sharma A, Naziruddin B, Cui C, Martin MJ, Xu H, Wan H, Lei Y, Harrison C,
Yin J, Okabe J, Mathews C, Stark A, Adams CS, Houtz J, Wiseman BS, Byrne
GW, Logan JS. Pig cells that lack the gene for alpha1-3 galactosyltransferase
express low levels of the gal antigen. Transplantation. 2003;75:430–6.
38. Lai L, Kolber-Simonds D, Park KW, Cheong HT, Greenstein JL, Im GS, Samuel
M, Bonk A, Rieke A, Day BN, Murphy CN, Carter DB, Hawley RJ, Prather RS.
Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear
transfer cloning. Science. 2002;295:1089–92.
39. Huai G, Qi P, Yang H, Wang Y. Characteristics of alpha-gal epitope, anti-gal
antibody, alpha1,3 galactosyltransferase and its clinical exploitation (review).
Int J Mol Med. 2016;37:11–20.
40. Milland J, Christiansen D, Lazarus BD, Taylor SG, Xing PX, Sandrin MS. The
molecular basis for galalpha(1,3) gal expression in animals with a deletion of
the alpha1,3galactosyltransferase gene. J Immunol. 2006;176:2448–54.
Tanihara et al. BMC Biotechnology           (2020) 20:40 Page 10 of 11
41. Butler JR, Skill NJ, Priestman DL, Platt FM, Li P, Estrada JL, Martens GR,
Ladowski JM, Tector M, Tector AJ. Silencing the porcine iGb3s gene does
not affect Galalpha3Gal levels or measures of anticipated pig-to-human and
pig-to-primate acute rejection. Xenotransplantation. 2016;23:106–16.
42. Hai T, Teng F, Guo R, Li W, Zhou Q. One-step generation of knockout pigs
by zygote injection of CRISPR/Cas system. Cell Res. 2014;24:372–5.
43. Burkard C, Lillico SG, Reid E, Jackson B, Mileham AJ, Ait-Ali T, Whitelaw CB,
Archibald AL. Precision engineering for PRRSV resistance in pigs:
macrophages from genome edited pigs lacking CD163 SRCR5 domain are
fully resistant to both PRRSV genotypes while maintaining biological
function. PLoS Pathog. 2017;13:e1006206.
44. Hirata M, Tanihara F, Wittayarat M, Hirano T, Nguyen NT, Le QA, Namula Z,
Nii M, Otoi T. Genome mutation after introduction of the gene editing by
electroporation of Cas9 protein (GEEP) system in matured oocytes and
putative zygotes. Vitro Cell Dev Biol Anim. 2019;55:237–42.
45. Su X, Chen W, Cai Q, Liang P, Chen Y, Cong P, Huang J. Production of non-
mosaic genome edited porcine embryos by injection of CRISPR/Cas9 into
germinal vesicle oocytes. J Genet Genomics. 2019;46:335–42.
46. Onuma A, Fujii W, Sugiura K, Naito K. Efficient mutagenesis by CRISPR/Cas
system during meiotic maturation of porcine oocytes. J Reprod Dev. 2017;
63:45–50.
47. Byrne G, Ahmad-Villiers S, Du Z, McGregor C. B4GALNT2 and
xenotransplantation: a newly appreciated xenogeneic antigen.
Xenotransplantation. 2018;25:e12394.
48. Nguyen DH, Tangvoranuntakul P, Varki A. Effects of natural human
antibodies against a nonhuman sialic acid that metabolically incorporates
into activated and malignant immune cells. J Immunol. 2005;175:228–36.
49. Hurh S, Kang B, Choi I, Cho B, Lee EM, Kim H, Kim YJ, Chung YS, Jeong JC,
Hwang JI, Kim JY, Lee BC, Surh CD, Yang J, Ahn C. Human antibody
reactivity against xenogeneic N-glycolylneuraminic acid and galactose-
alpha-1,3-galactose antigen. Xenotransplantation. 2016;23:279–92.
50. Martens GR, Reyes LM, Li P, Butler JR, Ladowski JM, Estrada JL, Sidner RA,
Eckhoff DE, Tector M, Tector AJ. Humoral reactivity of renal transplant-
waitlisted patients to cells from GGTA1/CMAH/B4GalNT2, and SLA class I
knockout pigs. Transplantation. 2017;101:e86–92.
51. Estrada JL, Martens G, Li P, Adams A, Newell KA, Ford ML, Butler JR, Sidner
R, Tector M, Tector J. Evaluation of human and non-human primate
antibody binding to pig cells lacking GGTA1/CMAH/beta4GalNT2 genes.
Xenotransplantation. 2015;22:194–202.
52. Fischer K, Rieblinger B, Hein R, Sfriso R, Zuber J, Fischer A, Klinger B, Liang
W, Flisikowski K, Kurome M, Zakhartchenko V, Kessler B, Wolf E, Rieben R,
Schwinzer R, Kind A, Schnieke A. Viable pigs after simultaneous inactivation
of porcine MHC class I and three xenoreactive antigen genes GGTA1, CMAH
and B4GALNT2. Xenotransplantation. 2019:e12560.
53. Zhang R, Wang Y, Chen L, Wang R, Li C, Li X, Fang B, Ren X, Ruan M, Liu J,
Xiong Q, Zhang L, Jin Y, Zhang M, Liu X, Li L, Chen Q, Pan D, Li R, Cooper
DKC, Yang H, Dai Y. Reducing immunoreactivity of porcine bioprosthetic
heart valves by genetically-deleting three major glycan antigens, GGTA1/
beta4GalNT2/CMAH. Acta Biomater. 2018;72:196–205.
54. Liu F, Liu J, Yuan Z, Qing Y, Li H, Xu K, Zhu W, Zhao H, Jia B, Pan W, Guo J,
Zhang X, Cheng W, Wang W, Zhao HY, Wei HJ. Generation of GTKO
Diannan miniature pig expressing human complementary regulator
proteins hCD55 and hCD59 via T2A peptide-based Bicistronic vectors and
SCNT. Mol Biotechnol. 2018;60:550–62.
55. Cho B, Koo OJ, Hwang JI, Kim H, Lee EM, Hurh S, Park SJ, Ro H, Yang J, Surh
CD, D’Apice AJ, Lee BC, Ahn C. Generation of soluble human tumor necrosis
factor-alpha receptor 1-fc transgenic pig. Transplantation. 2011;92:139–47.
56. Kim GA, Lee EM, Cho B, Alam Z, Kim SJ, Lee S, Oh HJ, Hwang JI, Ahn C, Lee
BC. Generation by somatic cell nuclear transfer of GGTA1 knockout pigs
expressing soluble human TNFRI-fc and human HO-1. Transgenic Res. 2019;
28:91–102.
57. Park SJ, Cho B, Koo OJ, Kim H, Kang JT, Hurh S, Kim SJ, Yeom HJ, Moon J,
Lee EM, Choi JY, Hong JH, Jang G, Hwang JI, Yang J, Lee BC, Ahn C.
Production and characterization of soluble human TNFRI-fc and human HO-
1(HMOX1) transgenic pigs by using the F2A peptide. Transgenic Res. 2014;
23:407–19.
58. Zhang J, Xie C, Lu Y, Zhou M, Qu Z, Yao D, Qiu C, Xu J, Pan D, Dai Y, Hara
H, Cooper DKC, Ma S, Li M, Cai Z, Mou L. Potential antigens involved in
delayed Xenograft rejection in a Ggta1/Cmah Dko pig-to-monkey model.
Sci Rep. 2017;7:10024.
59. Watanabe H, Sahara H, Nomura S, Tanabe T, Ekanayake-Alper DK, Boyd LK,
Louras NJ, Asfour A, Danton MA, Ho SH, Arn SJ, Hawley RJ, Shimizu A,
Nagayasu T, Ayares D, Lorber MI, Sykes M, Sachs DH, Yamada K. GalT-KO pig
lungs are highly susceptible to acute vascular rejection in baboons, which
may be mitigated by transgenic expression of hCD47 on porcine blood
vessels. Xenotransplantation. 2018;25:e12391.
60. Meier RPH, Muller YD, Balaphas A, Morel P, Pascual M, Seebach JD, Buhler
LH. Xenotransplantation: back to the future? Transpl Int. 2018;31:465–77.
61. Nguyen TV, Tanihara F, Do L, Sato Y, Taniguchi M, Takagi M, Van Nguyen T,
Otoi T. Chlorogenic acid supplementation during in vitro maturation
improves maturation, fertilization and developmental competence of
porcine oocytes. Reprod Domest Anim. 2017;52:969–75.
62. Naito Y, Hino K, Bono H, Ui-Tei K. CRISPRdirect: software for designing CRIS
PR/Cas guide RNA with reduced off-target sites. Bioinformatics. 2015;31:
1120–3.
63. Cradick TJ, Qiu P, Lee CM, Fine EJ, Bao G. COSMID: a web-based tool for
identifying and validating CRISPR/Cas off-target sites. Mol Ther Nucleic
Acids. 2014;3:e214.
64. Onishi A, Iwamoto M, Akita T, Mikawa S, Takeda K, Awata T, Hanada H, Perry
AC. Pig cloning by microinjection of fetal fibroblast nuclei. Science. 2000;
289:1188–90.
65. Bennett GL, Leymaster KA. Integration of ovulation rate, potential
embryonic viability and uterine capacity into a model of litter size in swine.
J Anim Sci. 1989;67:1230–41.
66. Bolet G, Botte FM, Locatelli A, Gruand J, Terqui M, Berthelot F. Components
of prolificacy in hyperprolific large white sows compared with the Meishan
and large white breeds. Genet Sel Evol. 1986;18:333–42.
67. Machaty Z, Day BN, Prather RS. Development of early porcine embryos
in vitro and in vivo. Biol Reprod. 1998;59:451–5.
68. Pinello L, Canver MC, Hoban MD, Orkin SH, Kohn DB, Bauer DE, Yuan GC.
Analyzing CRISPR genome-editing experiments with CRISPResso. Nat
Biotechnol. 2016;34:695–7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Tanihara et al. BMC Biotechnology           (2020) 20:40 Page 11 of 11
